A Phase 1/2, Open-Label, Dose-Escalation Trial of GEN3013 in Patients with Relapsed, Progressive or Refractory B-Cell Lymphoma
MD Anderson Study Status
The trial is a global, multi-center safety trial of epcoritamab, an antibody also known as GEN3013 (DuoBody®-CD3xCD20). The trial consists of two parts: a dose-escalation part (Phase 1, first-in-human (FIH)) and an expansion part (Phase 2a). All trial participants will get epcoritamab.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Diffuse Large B-cell Lymphoma, High-grade B-cell Lymphoma, Primary Mediastinal Large B-cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Small Lymphocytic Lymphoma, Marginal Zone Lymphoma
For general questions about clinical trials: